Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
ATC code | P01CB01 (WHO) QP51AB01 (WHO) |
Identifiers | |
|
|
Synonyms | meglumine antimonate |
CAS Number | 133-51-7 |
PubChem (CID) | 64953 |
ChemSpider | 58479 |
UNII | 75G4TW236W |
ChEMBL | CHEMBL239129 |
NIAID ChemDB | 008733 |
ECHA InfoCard | 100.004.645 |
Chemical and physical data | |
Formula | Variable |
Molar mass | Variable |
3D model (Jmol) | Interactive image |
|
|
|
|
(what is this?) |
Meglumine antimoniate is a medicine used to leishmaniasis. This include visceral, mucocutaneous, and cutaneous leishmaniasis. It is given by injection into a muscle or into the area infected.
Side effects include loss of appetite, nausea, abdominal pain, cough, feeling tired, muscle pains, irregular heartbeat, and kidney problems. It should not be used in people with significant heart, liver, or kidney problems. It is not recommended during breastfeeding. It belongs to a group of medications known as the pentavalent antimonials.
Meglumine antimoniate came into medical use in 1946. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is about 4.32 USD per vial as of 2014. It is available in Southern Europe and Latin America but not the United States.
It is manufactured by Aventis and sold as Glucantime in France, and Glucantim in Italy.